Related Experiment Video
Updated: Jan 10, 2026

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
Enhancing cardiovascular risk prediction in hypertensive adults: a 3PM-based evaluation of insulin resistance and
Yulong Lan1,2, Zhaogui Wu3, Dan Wu1,2
1Department of Cardiology, Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong China.
Insights
Insulin resistance (IR) and arterial stiffness synergistically increase atherosclerotic cardiovascular disease (ASCVD) risk in hypertension patients. Combining these biomarkers improves risk prediction and enables personalized preventive strategies.
Area of Science:
- Cardiovascular Medicine
- Metabolic Syndrome
- Hypertension Research
Background:
- Hypertension management is complicated by coexisting insulin resistance (IR) and arterial stiffness.
- These conditions are silent, synergistic drivers of atherosclerotic cardiovascular disease (ASCVD).
- Understanding their combined impact is crucial for effective ASCVD risk stratification.
Purpose of the Study:
- To evaluate the joint impact of IR and arterial stiffness on ASCVD risk in hypertensive adults.
- To assess the utility of these biomarkers in predictive, preventive, and personalized medicine (PPPM) strategies.
Main Methods:
- Prospective cohort study of 30,094 hypertensive adults.
- Insulin resistance assessed via triglyceride-glucose (TyG) index.
- Arterial stiffness measured by brachial-ankle pulse wave velocity (baPWV).
- Time-to-event analyses for ASCVD incidence.
Main Results:
- A median 5.6-year follow-up observed 1655 ASCVD cases.
- Elevated TyG index showed a dose-response relationship with ASCVD risk across baPWV strata.
- Individuals with both elevated TyG and baPWV had significantly higher ASCVD risk (HR: 1.93, 95% CI: 1.66-2.25).
- A significant additive interaction (33.4% of joint risk) was identified.
- Combined biomarkers improved model discrimination (C-index: 0.68) and reclassification (NRI: 18.63%).
Conclusions:
- Insulin resistance and arterial stiffness have a synergistic effect on ASCVD risk.
- Integrating these biomarkers into predictive models enhances early identification of high-risk hypertensive patients.
- This dual-biomarker approach supports PPPM for optimizing cardiovascular outcomes through tailored interventions.
Objective:
Hypertension management remains challenging due to coexisting insulin resistance (IR) and arterial stiffness-two silent yet synergistic drivers of atherosclerotic cardiovascular disease (ASCVD). This study aimed to evaluate their joint impact on ASCVD risk and assess their utility in predictive, preventive, and personalized strategies.
Methods:
In this prospective cohort study of 30,094 adults with hypertension, IR was assessed using the triglyceride-glucose (TyG) index (calculated as ln [TG (mg/dL) × FBG (mg/dL)/2]) and arterial stiffness via brachial-ankle pulse wave velocity (baPWV). Time-to-event analyses examined their individual and combined associations with ASCVD incidence.
Results:
Over a median 5.6-year follow-up, 1655 ASCVD cases occurred. TyG exhibited a dose-response relationship with ASCVD across baPWV strata. Each 1-SD increase in TyG was associated with a higher ASCVD risk in the elevated baPWV subgroup (HR: 1.17, 95% CI: 1.07-1.27) than in the normal baPWV subgroup (HR: 1.11, 95% CI: 1.02-1.21). A significant additive interaction was observed: individuals with both elevated TyG and baPWV had the highest ASCVD risk (HR: 1.93, 95% CI: 1.66-2.25), with 33.4% of the joint risk attributable to their interaction. Adding both biomarkers to traditional models improved discrimination (C-index: 0.66 to 0.68) and reclassification (NRI: 18.63%, P < 0.001).
Conclusions:
This study reveals a synergistic effect of IR and arterial stiffness on ASCVD risk and provides strong support for their integration into predictive models. This dual-biomarker approach enables early identification of high-risk hypertensive phenotypes and aligns with the predictive, preventive, and personalized medicine (PPPM) paradigm to optimize cardiovascular outcomes through tailored intervention.
Supplementary Information:
The online version contains supplementary material available at 10.1007/s13167-025-00421-8.
Related Concept Videos
Hypertension III: Clinical Manifestations and Diagnostic Studies
Peripheral Artery Disease III: Interprofessional Care
Assessment of blood pressure in brachial artery(two-step method)
Atherosclerosis III: Management
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Coronary Artery Disease I: Introduction

